Ke Su (科苏)科苏
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 扬子江药业集团广州海瑞药业有限公司Chinese legal name: 扬子江药业集团广州海瑞药业有限公司
主要成分Active Ingredients
- 厄贝沙坦CEbei Shatan
药物知识说明
厄贝沙坦C是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括：厄贝沙坦c。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品：厄贝沙坦c-25f15f36成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 科苏) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Explore other medicines containing the same ingredient: 厄贝沙坦c productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 科苏Recorded Chinese name: 科苏
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 75mg75 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
生产企业Manufacturer
- 扬子江药业集团广州海瑞药业有限公司Chinese legal name: 扬子江药业集团广州海瑞药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20073595
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20073595
Manufacturer
Chinese legal name: 扬子江药业集团广州海瑞药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20073595
生产企业
扬子江药业集团广州海瑞药业有限公司(国产)
适应症
本品用于高血压病。
用法用量
起始剂量为0.15g/次/日，根据病情可增至0.3g/次/日。
不良反应
1.常见不良反应为头痛眩晕心悸等偶有咳嗽一般程度都是轻微的呈一过性多数患者继续服药都能耐受罕有荨麻疹及血管神经性水肿发生
2.文献报道科苏不良反应发生率大于1％的有消化不良/胃灼热感腹泻骨骼肌疼痛疲劳和上呼吸道感染但与空白对照组比没有显著性差异大于1％但低于对照组发生率的有腹痛焦虑/神经质胸痛咽炎恶心呕吐皮疹和心动过速等低血压和直立性低血压发生率约为0.4％
禁忌
1.对本品成分过敏者禁用。
2.妊娠和哺乳期妇女禁用。
注意事项
1.开始治疗前应纠正血容量不足和(或)钠的缺失
2.肾功能不全的患者可能需要减少科苏的剂量并且要注意血尿素氮血清肌酐和血钾的变化作为肾素-血管紧张素-醛固酮抑制的结果个别敏感的患者可能产生肾功能变化
3.肝功能不全老年患者使用科苏时不需调节剂量
4.厄贝沙坦不能通过血液透析被排出体外
5.儿科使用尚没有小于18岁患者用药安全性的资料
贮藏
密封，在阴凉干燥处保存。
规格
75mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.